Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis

Treister-Goltzman, Yulia; Yarza, Shaked; Peleg, Roni

doi:10.23736/s2724-6507.20.03197-1

Cited by 14 publications

(17 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, one prospective cohort study enrolling 331 EC patients with median follow-up of 35 months have found that women with the history of hypothyroidism had improved overall survival (adjusted HR 0.22, 95%CI 0.06-0.74), cancer-specific survival (adjusted HR 0.21, 95%CI 0.05-0.98) and recurrence-free survival (adjusted HR 0.17, 95%CI 0.04-0.77) than those without [35]. Dyslipidemia is one of the most common metabolic disorders in hypothyroidism including increased level of total cholesterol (TC), low density lipoprotein (LDL), and triglycerides (TG) were significantly higher and reduced high-density lipoprotein (HDL) level compared to euthyroid individuals [36]. Both decreased thyroid hormone (TH) and increased TSH act on lipid metabolism through regulation of production and clearance of cholesterol in the liver [37].…”

Section: Obesity and Other Metabolic Diseases In Ecmentioning

confidence: 99%

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

Huang

Fan

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Endometrial cancer (EC) is a common gynecological cancer that endangers women health. Although substantial progresses of EC management have been achieved in recent years, the incidence of EC still remains high. Obesity has been a common phenomenon worldwide that increases the risk of EC. However, the mechanism associating obesity and EC has not been fully understood. Metabolic reprogramming as a remarkable characteristic of EC is currently emerging. As the primary factor of metabolic syndrome, obesity promotes insulin resistance, hyperinsulinemia and hyperglycaemia. This metabolic disorder remodels systemic status, which increases EC risk and is related with poor prognosis. Glucose metabolism in EC cells is complex and mediated by glycolysis and mitochondria to ensure energy requirement. Factors that affect glucose metabolism may have an impact on EC initiation and progression. In this study, we review the glucose metabolic reprogramming of EC not only systemic metabolism but also inherent tumor cell metabolism. In particular, the role of glucose metabolic regulation in malignant properties of EC will be focused. Understanding of metabolic profile and glucose metabolism-associated regulation mechanism in EC may provide novel perspective for treatment.

show abstract

Section: Obesity and Other Metabolic Diseases In Ecmentioning

confidence: 99%

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

Huang

Fan

et al. 2023

J Transl Med

View full text Add to dashboard Cite

show abstract

“…To date, severe SCH with serum TSH levels above 10 mIU/L (Grade 2) is associated with hyperlipidemia [55]. For mild SCH patients with serum TSH levels below 10 mIU/L (Grade 1), a systematic review of the studies and a meta-analysis for 35 case control and cohort studies was recently performed and reported that total cholesterol, low density lipoprotein, and triglycerides were significantly higher and that highdensity lipoprotein was significantly lower in Grade 1 SCH patients compared to euthyroid individuals [56]. Randomized, placebo-controlled trials designed to assess whether LT4 supplementation for patients with SCH is beneficial against dyslipidemia also had pro [57][58][59] and con [60,61] results.…”

Section: Dyslipidemiamentioning

confidence: 99%

Update on subclinical thyroid dysfunction

Hashimoto

2022

Endocr J

View full text Add to dashboard Cite

Subclinical thyroid dysfunction is defined by serum thyroid-stimulating hormone (TSH) levels either greater or less than the reference range with normal thyroxine (T4) concentrations, and consists of subclinical hypothyroidism (SCH) and subclinical hyperthyroidism (SCHyper). For the proper diagnosis of SCH, it is most important to be able to correctly evaluate the serum TSH levels, which have numerous unique characteristics. We also need to be versed in TSH harmonization, which was recently launched world-wide. In this review, we will attempt to determine the best clinical approaches to the treatment of subclinical thyroid dysfunction based on recent guidelines published from several countries and novel findings of several recent large-scale clinical studies.

show abstract

“…Hyperlipidemia is a significant risk factor for atherosclerosis; elevated TSH is linked to higher LDL, higher serum triglycerides (TGs), and reduced breakdown of cholesterol. This could contribute to the dyslipidemia observed with SCH [4,5] .…”

Section: Introductionmentioning

confidence: 99%

“…Subclinical hypothyroidism is accompanied by cardiovascular hazards such as hyperlipemia, diastolic hypertension, increase arterial stiffness, an elevated C-reactive protein, and endothelial dysfunction [4,5] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Subclinical Hypothyroidism and Cardiovascular System

Maghrapy¹,

Deen²,

Roushdy

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Because of its high prevalence, subclinical hypothyroidism (SCH) has clinical significance as it is associated with many of the risks of atherosclerotic cardiovascular disease (CVD) due to its direct and indirect effect on lipid profile, diastolic function, and endothelial dysfunction. However, the link between SCH and CVD is still unknown.Objectives: This study aimed to evaluate the carotid intima media thickness (CIMT) and the lipid profile as evidence of endothelial dysfunction and atherosclerosis on patients with SCH. Patients and methods: The current study was a cross-section study carried out on 50 patients with SCH who were enrolled from the

show abstract

Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis

Cited by 14 publications

References 44 publications

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

Update on subclinical thyroid dysfunction

The Subclinical Hypothyroidism and Cardiovascular System

Contact Info

Product

Resources

About